Paola Fioretto

Padova, 35122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Diet-Induced Ceramide Remodeling as a Mechanistic Link to Cardiac Metabolic Dysfunction.

Diet-Induced Ceramide Remodeling as a Mechanistic Link to Cardiac Metabolic Dysfunction.

Journal: Nutrients

Published: June 03, 2026

HFpEF in Asia: Distinct Phenotypes, Shared Mechanisms, and Emerging Insights.

HFpEF in Asia: Distinct Phenotypes, Shared Mechanisms, and Emerging Insights.

Journal: JACC. Asia

Published: April 22, 2026

Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus.

Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus.

Journal: Advances in therapy

Published: March 09, 2026

Change in Effectiveness and Safety Parameters After Initiation of SGLT2 Inhibitors for Post-Transplant Diabetes Mellitus: A Real-World Observational Study.

Change in Effectiveness and Safety Parameters After Initiation of SGLT2 Inhibitors for Post-Transplant Diabetes Mellitus: A Real-World Observational Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: March 09, 2026

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Journal: Cardiovascular diabetology

Published: January 26, 2026

Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.

Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.

Journal: Advances in therapy

Published: December 18, 2025

The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.

The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: November 15, 2025

Healthcare cost offsets associated with empagliflozin for the treatment of chronic kidney disease in Italy: a budget impact analysis.

Healthcare cost offsets associated with empagliflozin for the treatment of chronic kidney disease in Italy: a budget impact analysis.

Journal: Journal of nephrology

Published: September 04, 2025

Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis.

Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis.

Journal: Cardiovascular diabetology. Endocrinology reports

Published: July 31, 2025

Association of Chrono-Nutritional Profiles with Weight Loss and Comorbidity Remission After Bariatric Surgery in Patients with Severe Obesity.

Association of Chrono-Nutritional Profiles with Weight Loss and Comorbidity Remission After Bariatric Surgery in Patients with Severe Obesity.

Journal: Nutrients

Published: June 30, 2025

Could the heparanase/TGF-β axis modulation be considered for the SGLT2 inhibitors cardioprotection in obesity? A hypothesis-generating report.

Could the heparanase/TGF-β axis modulation be considered for the SGLT2 inhibitors cardioprotection in obesity? A hypothesis-generating report.

Journal: Acta diabetologica

Published: June 11, 2025

Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR.

Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR.

Journal: Clinical kidney journal

Published: June 05, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026